Register for our free email digests:
Market Intelligence
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
An Expert’s Guide To Switching In Germany, Part 2: Improving The Reclassification Process
How Pfizer Achieved 'Switch Success' With Viagra and Nexium
Pfizer secured two of the biggest prescription-to-OTC switches in recent years with the reclassification of Viagra and Nexium. Michelle Riddalls, Pfizer's director of regulatory affairs in Europe, offers her advice to firms looking to emulate this 'switch success'.
Use Real World Evidence To Drive Innovation, IQVIA Advises
An Expert’s Guide To Switching In Germany, Part 1: Navigating The Reclassification Process
Elmar Kroth, scientific director of the German Medicines Manufacturers´ Association, the BAH, talks exclusively to HBW Insight about prescription-to-OTC switching in Germany and the association’s efforts to improve this process.
Petite ‘N Pretty Makeup For Kids As Young As Four? Opportunity Could Be Worth The Static
The Los Angeles-area startup is taking heat for its name, messaging and apparent target audience, consisting of kids as young as four or five, particularly those with an Instagram following. The brand’s critics acknowledge that child influencers are an undeniable reality, and as Petite ‘N Pretty attests, they’re both highly effective and affordable.
Unilever Names New CEO; Sexy Hair’s $2.3m ‘Sulfate-Free’ Settlement; More Cosmetics News In Brief
Henkel’s Sexy Hair Concepts and Ulta will settle with plaintiffs over alleged “sulfate-free” deception, to the tune of $2.3m; Unilever’s Dermalogica is suing Target for unauthorized selling of diverted products. More cosmetics news in brief.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.